PubMed ID:
27208344
Public Release Type:
Journal
Publication Year: 2016
Affiliation: Emory Transplant Center, Emory University, Atlanta, GA.
DOI:
https://doi.org/10.2337/dc15-1988
Authors:
Senior PA,
Alejandro R,
Bellin MD,
Bridges ND,
Chaloner K,
Clarke WR,
Clinical Islet Transplantation Consortium,
Czarniecki CW,
Eggerman TL,
Goldstein JS,
Hering BJ,
Hunsicker LG,
Kaufman DB,
Korsgren O,
Larsen CP,
Luo X,
Markmann JF,
Naji A,
Oberholzer J,
Posselt AM,
Rickels MR,
Ricordi C,
Robien MA,
Shapiro AM,
Stock PG,
Turgeon NA
Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50-80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment.